FDA approves Alzheimer’s medication that delayed cognitive decline in clinical trials
Lecanemab, a treatment for Alzheimer’s disease, received an expedited approval from the Food and Drug Administration on Friday. This is the second treatment from Biogen and its Japanese partner Eisai to receive an early green light in less than two years. After clinical trial results that were published in November showed that lecanemab slows cognitive…